📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Praticien-chercheur
9 articles scientifiques publiés — formation continue solide
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Rheumatology (Oxford, England) · 2022
Abstract Objective To compare the risk of diverticulitis and gastrointestinal perforation (GIP) in RA treated with tocilizumab (TCZ) compared with rituximab (RTX) and abatacept (ABA). Methods We conducted a population-based study using three observational French registries on TCZ, RTX and ABA in RA. Using a propensity score approach, we compared the risk of diverticulitis or GIP in these patients. Results With inverse probability weighting, there was an increased risk of diverticulitis in TCZ-treated patients compared with RTX- or ABA-treated patients [hazard ratio (HR)=3.1 (95% CI: 1.5, 6.3), P =0.002]. Moreover, patients treated with TCZ had also an increased risk of GIP due to diverticulitis compared with those treated with RTX or ABA [HR=3.8 (1.1–13.6), P =0.04], resulting in an overall increased risk of GIP [HR=2.9 (1.1–7.8), P =0.03], while no significant increased risk of GIP due to any other aetiology was found in TCZ treated patients. Diverticulitis and GIP occurred earlier with TCZ than other drugs after the last perfusion (P =0.01), with atypical clinical presentation (slow transit in 30%, P =0.04) and lower acute-phase reactants at the time of the event (P =0.005). Conclusion TCZ for RA was associated with increased odds of diverticulitis as well as GIP due to diverticulitis as compared with RTX and ABA. Our study confirms the increased odds of GIP in patients receiving TCZ, which might be explained by an increased risk of diverticulitis with misleading clinical presentation.
The Journal of rheumatology · 1995
Pain management nursing : official journal of the American Society of Pain Management Nurses · 2015
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Reumatologia clinica · 2021 · Journal Article
González Fernández M, Villamañán E, Jiménez-Nácher I, Moreno F, et al.
International journal of clinical pharmacy · 2018 · Journal Article
González-Fernández M, Villamañán E, Jiménez-Nácher I, Moreno F, et al.
La Semana medica · 1960 · Journal Article
HERRERO AG
Rheumatology (Oxford, England) · 2021 · Comparative Study
Acebes C, Rubio L, Román A, Herrero A, et al.
Pain management nursing : official journal of the American Society of Pain Management Nurses · 2015 · Journal Article
Montesó-Curto P, García-Martínez M, Gómez-Martínez C, Ferré-Almo S, et al.
Rheumatology (Oxford, England) · 2022 · Comparative Study
Rempenault C, Lukas C, Combe B, Herrero A, et al.
International clinical psychopharmacology · 2025 · Case Reports
Andreu H, Serra-Sarró B, Bueno L, de Juan Ò, et al.
Journal of clinical pharmacy and therapeutics · 2016 · Comparative Study
Varela H, Villamañán E, Plasencia C, Romero JA, et al.
The Journal of rheumatology · 1995 · Journal Article
Perez-Ruiz F, Calabozo M, Alonso-Ruiz A, Herrero A, et al.